Home The Word Brain	My Amedeo FAQ Privacy About
	As of October 2023, Amedeo had 12,263 active subscribers

Prostate Cancer

Free Subscription 06.11.2023 1 Anticancer Res 2 BJU Int 3 BMC Urol 1 Br J Cancer 1 Cancer 1 Discov Oncol 2 Eur J Radiol 2 Eur Urol 2 Int J Cancer 4 Int J Urol 1 J Clin Oncol 1 J Natl Med Assoc 1 Nat Rev Urol 1 Oncol Rep 1 PLoS One 9 Prostate 1 Urol Int

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Anticancer Res

1. YAMAMOTO T, Umezawa R, Shimada S, Takahashi N, et al
   The Impact of Pathological Grade Group 3 on Relapse-free Survival After Salvage Radiotherapy for Postoperative Prostate Cancer.
   Anticancer Res. 2023;43:5115-5125.
   PubMed         Abstract available
   
   

   
   BJU Int

2. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
   Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
   BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
   PubMed         Abstract available
   
   
3. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
   CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
   BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
   PubMed         Abstract available
   
   

   
   BMC Urol

4. GARIN O, Kowalski C, Zamora V, Roth R, et al
   Patient-reported outcomes before treatment for localized prostate cancer: are there differences among countries? Data from the True North Global Registry.
   BMC Urol. 2023;23:178.
   PubMed         Abstract available
   
   
5. SEMBA R, Uchida K, Hirokawa Y, Shiraishi T, et al
   Short-term prognosis of low-risk prostate cancer patients is favorable despite the presence of pathological prognostic factors: a retrospective study.
   BMC Urol. 2023;23:174.
   PubMed         Abstract available
   
   
6. WANG G, Wang X, Du H, Wang Y, et al
   Prediction model of gleason score upgrading after radical prostatectomy based on a bayesian network.
   BMC Urol. 2023;23:159.
   PubMed         Abstract available
   
   

   
   Br J Cancer

7. FENG X, Zhang Y, Vaselkiv JB, Li R, et al
   Modifiable risk factors for subsequent lethal prostate cancer among men with an initially negative prostate biopsy.
   Br J Cancer. 2023 Oct 28. doi: 10.1038/s41416-023-02472.
   PubMed         Abstract available
   
   

   
   Cancer

8. NIERENGARTEN MB
   Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
   Cancer. 2023;129:3516.
   PubMed        
   
   

   
   Discov Oncol

9. BIAN Q, Li B, Zhang L, Sun Y, et al
   Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer.
   Discov Oncol. 2023;14:196.
   PubMed         Abstract available
   
   

   
   Eur J Radiol

10. SINGH S, Giganti F, Dickinson L, Rogers H, et al
    Prostate MR image quality of apparent diffusion coefficient maps versus fractional intracellular volume maps from VERDICT MRI using the PI-QUAL score and a dedicated Likert scale for artefacts.
    Eur J Radiol. 2023;168:111109.
    PubMed         Abstract available
    
    
11. FLEMING H, Dias AB, Talbot N, Li X, et al
    Inter-reader variability and reproducibility of the PI-QUAL score in a multicentre setting.
    Eur J Radiol. 2023;168:111091.
    PubMed         Abstract available
    
    

    
    Eur Urol

12. EAPEN RS, Buteau JP, Jackson P, Mitchell C, et al
    Administering [(177)Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study.
    Eur Urol. 2023 Oct 25:S0302-2838(23)03087-7. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available
    
    
13. DE VOS II, Remmers S, Hogenhout R, Roobol MJ, et al
    Prostate Cancer Mortality Among Elderly Men After Discontinuing Organised Screening: Long-term Results from the European Randomized Study of Screening for Prostate Cancer Rotterdam.
    Eur Urol. 2023 Oct 31:S0302-2838(23)03207-4. doi: 10.1016/j.eururo.2023.
    PubMed         Abstract available
    
    

    
    Int J Cancer

14. FREI K, Schecher S, Daher T, Horner N, et al
    Inhibition of the Cyclin K-CDK12 complex induces DNA damage and increases the effect of androgen deprivation therapy in prostate cancer.
    Int J Cancer. 2023 Nov 2. doi: 10.1002/ijc.34778.
    PubMed         Abstract available
    
    
15. NG HUNG SHIN B, Tan S, Rhee H, Chung E, et al
    Impact of the COVID-19 pandemic on delivery of prostate cancer care in Australia: An interrupted time series analysis.
    Int J Cancer. 2023 Nov 3. doi: 10.1002/ijc.34759.
    PubMed         Abstract available
    
    

    
    Int J Urol

16. YUASA T
    Editorial Comment to Bone-modifying agents are protective for symptomatic skeletal events in radium-223 treatment.
    Int J Urol. 2023;30:1034-1035.
    PubMed        
    
    
17. SHIRAISHI K
    Evaluation of sexual function after robot-assisted radical prostatectomy: A farewell to IIEF questionnaire.
    Int J Urol. 2023;30:959-967.
    PubMed         Abstract available
    
    
18. BLAS L, Shiota M, Matsumoto T, Hori Y, et al
    Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment.
    Int J Urol. 2023;30:1029-1034.
    PubMed         Abstract available
    
    
19. KOHADA Y, Hieda K, Miyamoto S, Tasaka R, et al
    Retrospective evaluation of the improvement in the urinary status-related quality of life after robot-assisted radical prostatectomy.
    Int J Urol. 2023;30:1020-1027.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

20. GONG J, Kim DM, De Hoedt AM, Bhowmick N, et al
    Disparities With Systemic Therapies for Black Men Having Advanced Prostate Cancer: Where Do We Stand?
    J Clin Oncol. 2023 Oct 27:JCO2300949. doi: 10.1200/JCO.23.00949.
    PubMed         Abstract available
    
    

    
    J Natl Med Assoc

21. MOUZANNAR A, Delgado J, Kwon D, Atluri VS, et al
    Racial disparity in the utilization of immunotherapy for advanced prostate cancer.
    J Natl Med Assoc. 2023 Oct 28:S0027-9684(23)00107.
    PubMed         Abstract available
    
    

    
    Nat Rev Urol

22. MORI JO, Elhussin I, Brennen WN, Graham MK, et al
    Prognostic and therapeutic potential of senescent stromal fibroblasts in prostate cancer.
    Nat Rev Urol. 2023 Oct 31. doi: 10.1038/s41585-023-00827.
    PubMed         Abstract available
    
    

    
    Oncol Rep

23. LEE DY, Lee S, Kim YS, Park S, et al
    Cyclosporin A inhibits prostate cancer growth through suppression of E2F8 transcription factor in a MELK?dependent manner.
    Oncol Rep. 2023;50:218.
    PubMed         Abstract available
    
    

    
    PLoS One

24. JOHANSSON P, Joneus P, Langenskiold S
    Causal inferences and real-world evidence: A comparative effectiveness evaluation of abiraterone acetate against enzalutamide.
    PLoS One. 2023;18:e0293000.
    PubMed         Abstract available
    
    

    
    Prostate

25. GOVINDAN S, Cheranda N, Riekhof F, Luo S, et al
    Effect of BMI and hemoglobin A1c on survival of veterans with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    Prostate. 2023 Nov 1. doi: 10.1002/pros.24644.
    PubMed         Abstract available
    
    
26. ALSAIDAN OA, Onobun E, Ye C, Lou L, et al
    Inhibition of N-myristoyltransferase activity promotes androgen receptor degradation in prostate cancer.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24645.
    PubMed         Abstract available
    
    
27. DI H, Wen Y
    Vasectomy and risk of prostate cancer: A Mendelian randomization study and confounder analysis.
    Prostate. 2023 Oct 31. doi: 10.1002/pros.24646.
    PubMed         Abstract available
    
    
28. FU W, Xu L, Chen Y, Zhang Z, et al
    Luteolin induces ferroptosis in prostate cancer cells by promoting TFEB nuclear translocation and increasing ferritinophagy.
    Prostate. 2023 Oct 30. doi: 10.1002/pros.24642.
    PubMed         Abstract available
    
    
29. MAHMOUD AM, Childs DS, Ahmed ME, Tuba Kendi A, et al
    Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis.
    Prostate. 2023 Oct 29. doi: 10.1002/pros.24643.
    PubMed         Abstract available
    
    
30. ECHEVERRIA CE, Oyarzun VI, Lopez-Cortes A, Cancino J, et al
    Biological role of fructose in the male reproductive system: Potential implications for prostate cancer.
    Prostate. 2023 Oct 27. doi: 10.1002/pros.24631.
    PubMed         Abstract available
    
    
31. ZENG J, Zhang Y, Xu R, Chen H, et al
    Nanomechanical-based classification of prostate tumor using atomic force microscopy.
    Prostate. 2023;83:1591-1601.
    PubMed         Abstract available
    
    
32. BELUE MJ, Blake Z, Yilmaz EC, Lin Y, et al
    Is prostatic adenocarcinoma with cribriform architecture more difficult to detect on prostate MRI?
    Prostate. 2023;83:1519-1528.
    PubMed         Abstract available
    
    
33. MIYAHIRA AK, Soule HR
    The 29th Annual Prostate Cancer Foundation Scientific Retreat Report.
    Prostate. 2023 Nov 1:e24640. doi: 10.1002/pros.24640.
    PubMed         Abstract available
    
    

    
    Urol Int

34. SHEN C, Zhang DL, Cheng XL, Zhang WC, et al
    Urological Tumor: A Narrative Review of Tertiary Lymphatic Structures.
    Urol Int. 2023;107:841-847.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.